Literature DB >> 15365144

Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy.

Rachel Katz-Brull1, Robert E Lenkinski, Renaud A Du Pasquier, Igor J Koralnik.   

Abstract

MRI, 1H-MR spectroscopy, immunologic, and virologic studies were performed in search of prognostic factors of disease evolution in patients with progressive multifocal leukoencephalopathy (PML). Acute lesions of PML survivors showed twofold higher standard score of the ratio of myoinositol (a glial marker) to creatine compared with lesions in patients whose disease progressed. Concomitantly, JC virus-specific cytotoxic T lymphocytes were only detected in the blood of PML survivors. These results suggest that inflammation limits disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365144     DOI: 10.1212/01.wnl.0000137420.58346.9f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Proton MR spectroscopy of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome.

Authors:  V Cuvinciuc; G Martin-Blondel; B Marchou; F Bonneville
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

2.  Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells.

Authors:  Christian Wüthrich; Santosh Kesari; Woong-Ki Kim; Kenneth Williams; Rebecca Gelman; Derek Elmeric; Umberto De Girolami; Jeffrey T Joseph; Tessa Hedley-Whyte; Igor J Koralnik
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

3.  Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome.

Authors:  Michael N Khoury; Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Igor J Koralnik
Journal:  Brain       Date:  2013-10-01       Impact factor: 13.501

4.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

5.  A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients.

Authors:  Duško Kozić; Mladen Bjelan; Jasmina Boban; Jelena Ostojić; Vesna Turkulov; Aleksandar Todorović; Slobodanka Lemajić-Komazec; Snežana Brkić
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

6.  Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Authors:  S Gheuens; D R Smith; X Wang; D C Alsop; R E Lenkinski; I J Koralnik
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

Review 7.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

8.  Metabolic profile of PML lesions in patients with and without IRIS: an observational study.

Authors:  Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

9.  Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II.

Authors:  L Vedolin; I V D Schwartz; M Komlos; A Schuch; A C Puga; L L C Pinto; A P Pires; R Giugliani
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

Review 10.  CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome.

Authors:  M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.